• BioAlliance Pharma SA, of Paris, said it started its Phase III ReLive trial testing Livatag (doxorubicin Transdrug) in nearly 400 patients with hepatocellular carcinoma, who are resistant or intolerant to Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer AG).
Read More
GlaxoSmithKline plc's $2.6 billion acquisition offer for Rockville, Md.-based Human Genome Sciences Inc. (HGS) turned hostile recently when GSK announced that it would not participate in a strategic alternatives review process with HGS, and that it would instead commence its tender offer for all outstanding shares for $13 per share in cash, which it first put forward April 11.
Read More
Researchers at British biotechnology firm Immunocore Ltd., with academic colleagues, have come up with a method to break T-cell tolerance to cancer cells and target tumor-specific proteins, even when those proteins are expressed at very low levels.
Read More
LONDON – HatchTech Pty. Ltd. raised A$7.8 million (US$7.8 million) from existing investors, enabling it to push DeOvo, a metalloproteinase inhibitor for treating head lice, into a Phase III U.S. trial.
Read More
LONDON – F-Star GmbH named a new management team and is concentrating all its research and operational activities in Cambridge, UK, as it prepares to move the first product based on its novel bi-specific antibody technology into clinical development.
Read More
Shares in Mologen AG jumped 17 percent to a 52-week high Monday on news that the company's DNA-based cancer immunotherapy, MGN1703, hit the primary endpoint, a prolongation of progression-free survival (PFS), in a Phase II trial in patients with metastatic colorectal cancer (CRC).
Read More
LONDON – It may be possible to correct a defect in mitochondria that occurs in many cases of Parkinson's disease with the help of a humble vitamin, researchers in Belgium have discovered.
Read More
LONDON – Innovacell Biotechnologie AG raised €8.3 million (US$10.7 million) from existing shareholders as it began a Phase III study of ICES13, its autologous cell therapy for the treatment of stress urinary incontinence.
Read More
